Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,258

Document Document Title
WO/2018/166932A1
The present invention relates to arylamine derivatives which are substituted with diazanaphthalene groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to th...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/167468A1
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...  
WO/2018/167187A1
The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells an...  
WO/2018/163077A1
The invention relates to indanyl compounds, their pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising the same for the treatment, management and /or lessening severity of ...  
WO/2018/157842A1
The present invention provides a use of 2-(substituted phenylamino)benzoic acid FTO inhibitor in treating leukemia.  
WO/2018/159515A1
Provided is a method for producing a pentafluorosulfanyl aromatic compound represented by general formula (3), Ar-(SF5)k, (in the formula, Ar is a substituted or unsubstituted aryl group or heteroaryl group, and k is an integer between 1...  
WO/2018/157843A1
The preparation method provides 2-(substituted benzene matrix) aromatic formate FTO inhibitor, a preparation method therefor, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted benzene matrix)...  
WO/2018/157813A1
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...  
WO/2018/157981A1
The present invention relates to triarylamine compounds of general formula (I). The present invention further relates to methods for producing said compounds, oligomers, polymers or dendrimers and to formulations containing said compound...  
WO/2018/153379A1
A pharmaceutical composition comprising N-((5-((5-chloro-4-((naphthalene -2-yl)amino))pyrimidine-2-yl)amino)-2-((N-methyl-N-dimethyla minoethyl)amino)-4-methoxypheny)acrylamide, and a preparation method for the pharmaceutical composition.  
WO/2018/151633A1
The present invention relates to a method for producing a compound of formula I, where B is, independently, hydrogen or [see appropriate figure], wherein no more than one B is hydrogen; D is NR1 or O; R1 is H, R, C1-C4 alkyl, unsubstitut...  
WO/2018/151681A1
The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4- [4-(tr...  
WO/2018/148856A1
The present invention provides a compound of the Formula (1) below pharmaceutically acceptable salts of the compound of Formula (1), methods of treating patients for liver disease, and processes for preparing the compounds.  
WO/2018/151520A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has a high glass transition temperat...  
WO/2018/151985A1
The present invention provides compounds of the formula below, pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.  
WO/2018/147555A1
The present invention relates to: a method for preparing a 4,5-diamino-substituted pyrimidine derivative represented by chemical formula (1) defined in claim 1, the derivative being an intermediate for preparing a cephalosporin derivativ...  
WO/2018/143403A1
Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce au...  
WO/2018/140512A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...  
WO/2018/132326A1
Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hema...  
WO/2018/131690A1
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/128390A1
The present invention relates to a method for producing a 5-(3,6-dihydro-2,6-dioxo-4-trifluoromethyl-1(2H)-pyrimidinyl )phenylthiol compound. The production method according to the present invention enables provision of stable yield and ...  
WO/2018/128387A1
The present invention relates to a method for producing a 3-arly uracil compound. The production method according to the present invention can efficiently produce a 3-arly uracil compound by reducing a reaction time for the production of...  
WO/2018/128720A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/125961A1
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...  
WO/2018/124000A1
The present invention addresses the problem of providing a compound that, when used in the treatment of cystic fibrosis, which is caused by a mutation of a cystic fibrosis transmembrane conductance regulator (CFTR), which is a kind of ch...  
WO/2018/122775A1
The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions...  
WO/2018/124088A1
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...  
WO/2018/122559A1
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The invention also relates to methods of using said compounds and compositions comprising said compounds.  
WO/2018/121758A1
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.  
WO/2018/113584A1
Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and ca...  
WO/2018/119183A3
Provided herein are benzisothiazol, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives and related compounds as KRAS G12C inhibitors for treating e.g. lung cancer, pancre...  
WO/2018/114476A1
The present invention relates to an amidine containing at least one structure unit of formula (I) and to the use thereof as a catalyst for the cross-linking of a functional compound, in particular a polymer comprising silane groups. In a...  
WO/2018/115380A1
The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this...  
WO/2018/119183A2
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.  
WO/2018/118668A1
Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benz enesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are phar...  
WO/2018/118791A3
Novel quinazolinones useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said...  
WO/2018/107201A1
The invention relates to functionalized dihydro— and tetrahydro-quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or condi...  
WO/2018/108671A1
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...  
WO/2018/111738A1
Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonist...  
WO/2018/111990A1
The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally ...  
WO/2018/107200A1
The invention relates to functionalized quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or conditions related to heparanse...  
WO/2018/106606A1
The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.  
WO/2018/106284A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2018/102455A1
Disclosed herein are methods of treating cancer in a subject, wherein the subject is known to possess at least one genetic alteration in RET, comprising administering to the subject a therapeutically effective amount of N-[3-[(6,7-dimeth...  
WO/2018/102366A1
The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.  
WO/2018/100515A1
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.  
WO/2018/098348A1
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in ...  
WO/2018/096497A1
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, form...  

Matches 1 - 50 out of 25,258